Major Breakthrough! SYSU Identifies YAP1 Lactylation as Precise Cisplatin Resistance Biomarker for Bladder Cancer in Cell Reports
Major Breakthrough! SYSU Identifies YAP1 Lactylation as Precise Cisplatin Resistance Biomarker for Bladder Cancer in Cell Reports
2026-07-25
SYSU researchers confirmed YAP1-K90la lactylation triggers cisplatin resistance in bladder cancer, outperforming total YAP1 protein in predicting chemotherapy response.
The modification activates YAP1 transcription and blocks tumour ferroptosis via the FOSL1 pathway. Targeted peptide treatment restores cancer cell sensitivity to cisplatin. This discovery offers a promising biomarker and therapeutic target for drug-resistant bladder cancer.
We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.
